Observational studyCardiovascular and interventional radiology2026
Curative-Intent Cryoablation for Bone Metastases: Study Protocol for BOREALIS, a Prospective Multicentre Observational Investigation.
Observational study in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06480955 (BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCryoablation (CA) is a well-established, safe and effective palliative treatment for painful bone metastases (BM). Data exploring its curative potential (i.e. radical clearing of the target lesion) is however very scarce, mostly coming from small retrospective studies. The BOne metastases REgistry for patients undergoing cryoAbLation with curatIve purpoSe (BOREALIS) aims to address this shortcoming by collecting prospective, multicentric real-world data on the outcomes of curative-intent CA for bone metastases.
methodsBOREALIS is an observational cohort study designed to follow for 1 year up to 50 participants with BM (< 5 cm) from oligometastatic or bone oligo-progressive disease treated with curative-intent CA. The primary outcome measure is the 12-months local progression-free survival rate, assessed per lesion using the newly developed BOREALIS tumour response criteria. Secondary outcome measures include complete response rate, fracture-free, progression-free, and overall survival; safety; patient-reported pain; and health-related quality of life (HRQoL). The study will also evaluate the feasibility of a comprehensive procedure integrating, when indicated, biopsy and bone consolidation within the same CA session. Results will be reported using mainly descriptive statistics. Patient enrolment opened in April 2025.
conclusionBOREALIS intends to provide insights into the effectiveness of curative-intent CA for BM to inform the development of future clinical guidelines. BOREALIS is registered on ClinicalTrial.gov (NCT06480955).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.